CHEEVER CHARLIE E III purchased $54K of CVSI
CHEEVER CHARLIE E III purchased 5,440,926 shares of CV Sciences, Inc. (CVSI) at $0.01 across 5 trades over 2026-11-04 to 2026-11-11.
CV Sciences, Inc.
CV Sciences is a consumer wellness company that develops, manufactures, markets and sells hemp extracts, CBD products, herbal supplements and plant-based foods. Its brands include +PlusCBD™, with softgels, tinctures, topicals, gummies and pet products; +PlusHLTH™, a line of cannabinoid-free supplements; and Cultured Foods™ and Lunar Fox™, which offer plant-based foods. The company also manufactures encapsulated softgels and tinctures for supplement and nutrition businesses, including products made with customers’ formulations or its own. CV Sciences sells through its websites, distributors, brick-and-mortar retailers and e-tailers. Its hemp products are sold predominantly in North America, while plant-based foods are sold primarily in Europe. It makes money from manufacturing, marketing and distributing its consumer products, as well as contract manufacturing. Its primary offices and facilities are in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland.
CHEEVER CHARLIE E III purchased 5,440,926 shares of CV Sciences, Inc. (CVSI) at $0.01 across 5 trades over 2026-11-04 to 2026-11-11.
CV Sciences reported 3Q 2026 revenue of $3.03M, down 7% YoY, with net loss narrowing to $93K. Sales volume and prices declined due to state regulations and higher discounts, but gross margin improved to 50%. New products contributed 48.4% of revenue. A legal settlement gain of $500K also impacted results.
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CVSI (CV Sciences, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent CVSI coverage spans earnings, insider activity and corporate actions.
In the last 30 days, CVSI insiders filed 5 SEC Form 4 transactions — 5 purchases ($54K) and no sales. The most active reporter was CHEEVER CHARLIE E III with 5 filings.
The filing signals continued insider buying at very low prices, but it is small in dollar terms and lacks a new operational catalyst.
Earnings miss on revenue but loss improvement may limit downside.
Earnings miss and modest profit may weigh on the stock.
Cash inflow from settlement may provide modest liquidity but unlikely to move the stock significantly.
Significant insider buying may signal confidence and could support short-term price upside.
AlphAI scores every news story that mentions CVSI with an AI model for sentiment and relevance, and aggregates insider trades from CV Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CHEEVER CHARLIE E III purchased 5,440,926 shares of CV Sciences, Inc. (CVSI) at $0.01 across 5 trades over 2026-11-04 to 2026-11-11.
CV Sciences reported 3Q 2026 revenue of $3.03M, down 7% YoY, with net loss narrowing to $93K. Sales volume and prices declined due to state regulations and higher discounts, but gross margin improved to 50%. New products contributed 48.4% of revenue. A legal settlement gain of $500K also impacted results.
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously reported by the Company on February 12, 2025, the Company initiated an arbitration with JAMS against its former legal counsel. This case has been settled. Under the terms of the settlement, the Company has received $500,000, and the Company an
CHEEVER CHARLIE E III purchased 5,740,816 shares of CV Sciences, Inc. (CVSI) at $0.02 ($0.11M total) across 10 trades over 2026-07-16 to 2026-08-07.
CV Sciences (OTCQB:CVSI) welcomed federal legislation delaying hemp restrictions until December 11, 2026, providing Congress time to develop a regulatory framework. The company supports science-based standards for hemp-derived products and plans to engage with policymakers. CV Sciences is a consumer wellness company specializing in hemp extracts and natural ingredients.
CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ext
CV Sciences (OTCQB:CVSI) launched PlusHLTH.com, a direct-to-consumer site for its +PlusHLTH non-cannabinoid product line, expanding beyond its PlusCBDOil.com focus on hemp-derived CBD. The company says the site supports its “Health Intelligence” approach with science-backed education and plans to add new formulations and delivery formats.
CV Sciences, Inc. (OTCQB: CVSI) said it will report second-quarter 2026 results for the quarter ended June 30, 2026 after the market closes on Aug. 13, 2026. The company will host a conference call and webcast at 1:30 p.m. PT the same day, with a replay available through Aug. 20.